(placebo to lnp023 100 mg)

DRUG2 trials

Sponsors

Novartis Pharma AG

Conditions

Idiopathic Immune Complex Mediated Membranoproliferative Glomerulonephritis (IC-MPGN)complement 3 glomerulopathy

Phase 3

A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN)

RecruitingCTIS2022-502160-20-00

Novartis Pharma AGIdiopathic Immune Complex Mediated Membranoproliferative Glomerulonephritis (IC-MPGN)

Start: 2023-10-02Target: 41Updated: 2025-12-05

A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3glomerulopathy

RecruitingCTIS2023-509331-83-00

Novartis Pharma AGcomplement 3 glomerulopathy

Start: 2021-07-28Target: 37Updated: 2025-06-25